Vireo Growth Receivables 2023-2025 | VREOF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vireo Growth receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vireo Growth receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$229.7B
Boston Scientific (BSX)	$152.7B
Stryker (SYK)	$148.7B
EssilorLuxottica (ESLOY)	$131.4B
Medtronic (MDT)	$115.3B
Lonza Group Ag (LZAGY)	$51.1B
Haleon (HLN)	$44.7B
ResMed (RMD)	$37.3B
Agilent Technologies (A)	$35B
GE HealthCare Technologies (GEHC)	$34.4B
Terumo (TRUMY)	$24.6B
Koninklijke Philips (PHG)	$23.1B
Insulet (PODD)	$20.4B
Zimmer Biomet Holdings (ZBH)	$18.6B
Baxter (BAX)	$14.7B
Smith & Nephew SNATS (SNN)	$13.3B
Demant (WILYY)	$9B
Sunny Optical Technology (SNPTF)	$8.6B
Bio-Rad Laboratories (BIO)	$7B
Lantheus Holdings (LNTH)	$5.6B
Perrigo (PRGO)	$3.8B
Prestige Consumer Healthcare (PBH)	$3.8B
Haemonetics (HAE)	$3.6B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Envista Holdings (NVST)	$3.4B
ICU Medical (ICUI)	$3.3B
QuidelOrtho (QDEL)	$2.1B
LeMaitre Vascular (LMAT)	$1.9B
AtriCure (ATRC)	$1.5B
Acuren (TIC)	$1.4B